WellSpan THRIVE Cancer Quality of Life Program
WellSpan Study of Tracking Health and Resilience to Improve the Vitality of Individuals Experiencing Cancer [WellSpan-THRIVE]
This program will try a patient-focused quality-of-life survey to learn how cancer and its treatments affect adults newly diagnosed with cancer.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 1000 (estimated) |
| Ages | 18 Years and up |
| Sex | All |
| Sponsor | WellSpan Health Academic / other |
| Drugs / interventions | chemotherapy, radiation |
| Locations | 5 sites (Chambersburg, Pennsylvania and 4 other locations) |
| Trial ID | NCT07433660 on ClinicalTrials.gov |
What this trial studies
This observational registry will develop and implement a patient-centered quality-of-life (QOL) survey tailored for people with cancer, using direct patient input to capture what matters most in daily life. Eligible participants are adults with a new primary cancer diagnosis within the past six months, excluding non-melanoma skin cancers, primary brain tumors or metastases, and hematologic malignancies. Participants will complete standardized and patient-informed questionnaires at WellSpan oncology sites to document symptoms, function, and social and emotional impacts over time. Collected data will be used to better identify needs and inform supportive care for patients and families.
Who should consider this trial
Good fit: Adults aged 18 and older with a new primary cancer diagnosis within the past six months who can provide informed consent and complete questionnaires are ideal candidates.
Not a fit: Patients with primary non-melanoma skin cancer, primary brain or hematologic malignancies, severe cognitive impairment, or a life expectancy under 90 days are unlikely to benefit from participating.
Why it matters
Potential benefit: If successful, the survey could help clinicians and care teams identify unmet needs and target supportive services to improve patients' daily functioning and well-being.
How similar studies have performed: Patient-reported outcome instruments like the EORTC QLQ and FACT have been used successfully in cancer populations, so this work builds on established methods though the specific patient-centered survey may be novel.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Age 18 years and above * Primary cancer diagnosis (newly diagnosed within the past 6 months) * Able to sign informed consent. Exclusion Criteria: * Patients with age\<18 years, * Patients with primary non-melanoma skin, neurological malignancies (Brain or brain metastases), and primary hematological malignancies. * Patients with severe cognitive impairment, unable to sign informed consent or unable to complete quality of life questionnaire. * Patients with life expectancy of \<90 days, in the opinion of treating investigator.
Where this trial is running
Chambersburg, Pennsylvania and 4 other locations
- WellSpan Medical Oncology & Hematology — Chambersburg, Pennsylvania, United States (Recruiting)
- WellSpan Ephrata Cancer Center — Ephrata, Pennsylvania, United States (Recruiting)
- WellSpan Adams Cancer Center — Gettysburg, Pennsylvania, United States (Recruiting)
- WellSpan Sechler Family Cancer Center — Lebanon, Pennsylvania, United States (Recruiting)
- WellSpan York Cancer Center — York, Pennsylvania, United States (Recruiting)
Study contacts
- Principal investigator: Navesh Sharma, DO, PhD, FACRO — WellSpan Health
- Study coordinator: Joan K Moore, MSN, RN, OCN, CCRP
- Email: jmoore@wellspan.org
- Phone: 717-741-8124
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.